<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02374476</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 14-1827</org_study_id>
    <nct_id>NCT02374476</nct_id>
  </id_info>
  <brief_title>Bipolar Ventricular Tachycardia (VT) Study</brief_title>
  <official_title>Bipolar Catheter Ablation for the Treatment of Refractory Scar-Related Ventricular Arrhythmia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Srinivas Dukkipati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biosense Webster, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This non-randomized study will examine the safety and efficacy of irrigated bipolar
      radiofrequency (RF) ablation in the treatment of ventricular tachycardia (VT) in patients for
      whom standard VT unipolar RF ablation has been unsuccessful. VT is a serious abnormality of
      the heart's electrical system. Ablation is a procedure that cauterizes heart tissue using
      catheters (long tubes that can be moved within or along the outside of the heart).
      Cauterizing the heart tissue is accomplished by using heat to damage the abnormal heart
      tissue that is not working well so that it can stop affecting the rest of the heart. Usually,
      heat is delivered using a unipolar catheter, in which energy travels from the catheter tip to
      a grounding pad. This research study seeks to find out if a bipolar ablation catheter, in
      which the energy travels between two catheter tips on either side of the heart muscle, can be
      used to eliminate the arrhythmia when the unipolar ablation is unsuccessful. The hypothesis
      is that the increased current density and improved rates of transmural lesion creation seen
      with bipolar RF ablation will lead to successful arrhythmia termination with minimal or no
      increased risk of complication.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVE This study will examine the role of irrigated bipolar radiofrequency (RF)
      ablation for the treatment of intramural ventricular tachycardia in patients who have failed
      standard unipolar RF ablation. The hypothesis is that the increased current density and
      improved rates of transmural lesion creation seen with bipolar RF ablation will lead to
      successful arrhythmia termination with minimal or no increased risk of complication.

      INTRODUCTION, RATIONALE Radiofrequency (RF) ablation is the most commonly employed method for
      the catheter treatment of cardiac arrhythmias. Myocardial scar serves as the most frequent
      substrate for the genesis of both atrial and ventricular arrhythmia. Such scar frequently
      contains surviving myocyte bundles interspersed with fibrotic tissue, which leads to slow
      conduction. Areas of denser fibrosis cause conduction block. When appropriately arranged,
      conduction through or around these scars leads to the creation of a &quot;reentry&quot; circuit through
      which an arrhythmia is generated and maintained. Each reentry circuit contains within it an
      area called the isthmus, a portion of the circuit located in a position intimately related to
      the scar border zone. Electrical activation travels slowly through the isthmus before
      breaking out into normal myocardium. Ablation at the site of an isthmus will terminate a
      reentrant tachycardia.

      A variety of techniques, including electroanatomic mapping and activation, entrainment, and
      substrate mapping, are employed during electrophysiologic (EP) study to identify areas of
      myocardial scar and potential isthmus sites. Points or lines of ablation using RF energy are
      then created in an attempt to interrupt the reentry circuit. Typically, unipolar RF energy is
      applied via a catheter tip electrode to the endocardial or epicardial surface of the heart
      and grounded via an electrode pad placed on the patient's skin. RF energy in this setting is
      dispersed through the entirety of the tissue between catheter tip and grounding pad. The
      standard 7-French, 4-mm tip catheters are highly successful at ablating circuits located
      within a few millimeters of the catheter tip. A focal, 1mm area of resistive heating occurs
      within the myocardium immediately in contact with the catheter tip; myocardial cell death
      occurs several millimeters more deeply through passive, conductive heating, which spreads
      outward from the contact point.

      While the standard catheter is effective at the ablation of superficial arrhythmias, it has
      proven more problematic when used for deep myocardial sites or for creating transmural
      lesions. A number of alternatives have been developed in an attempt to access these sites.
      8-mm or 10-mm catheter tips are able to create larger zones of resistive heating, delivering
      direct RF energy to a larger area of myocardium. A larger interface between catheter tip and
      blood improves cooling and allows for the delivery of more power without a rise in impedence.
      The clinical use of these larger catheters can, however, be limited by rapid temperature
      rises at the catheter-tissue interface, resulting in thrombus formation, char, and &quot;steam
      pop&quot; rupture of the endocardial surface. The use of irrigated ablation catheters have
      improved upon the ability to deliver RF energy without a sustained rise in impedance. Both
      open irrigated- and closed-loop irrigated catheters circulate saline along the catheter
      tip-myocardial interface, allowing for continued delivery of RF current without thrombus
      formation at the endocardial surface. Intramyocardial temperature rises accordingly without a
      concomitant endocardial temperature surge, creating larger and deeper myocardial ablation
      zones. Catheters featuring a retractable needle tipped electrode with intramyocardial saline
      infusion have also shown promise as a means of accessing deep myocardial circuits in
      ventricular tachycardia ablation, but are not currently available in the US. Transcoronary
      ethanol ablation has also been employed with moderate success in patients with arrhythmias
      resistant to endocardial catheter ablation. This technology, however, grants only limited
      control over the size of the resulting infarct and is restricted by the need for perfusion of
      the scar zone by an accessible coronary artery.

      Nevertheless, there remain occasions in which an arrhythmia cannot be eliminated by standard
      unipolar ablation technique. This is seen most frequently due to deep intramural ventricular
      tachycardia, sometimes encountered following myocardial infarction. Both standard and
      alternative ablation strategies are frequently either unavailable or inadequate for
      termination of these arrhythmias.

      Recently, several centers have employed irrigated bipolar ablation (BA) to target arrhythmias
      not amenable to unipolar ablation. During BA, two catheters are connected to either pole of
      an RF generator, allowing either catheter to function as the &quot;active&quot; catheter and the other
      the &quot;return&quot; catheter. Rather than being dispersed between the catheter tip and a distant
      grounding pad, BA concentrates energy between two catheter tips positioned on opposing sides
      of a target scar. BA may thus improve lesion transmurality through synergistic, simultaneous
      heating and increased current density leading to concentrated thermal injury.

      Initial experience in the use of BA technology in mammalian hearts demonstrated that it could
      successfully be applied to create discrete areas of myocardial necrosis with minimal risk of
      complication. When compared to unipolar ablation, several studies suggested that BA could
      create larger areas of necrosis and transmural lesions with only rare episodes of
      perforation. Subsequent experience in human hearts was predominantly surgical: a large number
      of observational studies and reviews demonstrated the effectiveness and safety of BA in
      patients undergoing pulmonary vein isolation and Cox-Maze surgery as either isolated
      procedures or as adjuncts to valve replacement or coronary artery bypass surgery.

      Despite its broad use during surgical ablation, the application of BA during catheter-based
      therapies is limited. Recently, our group demonstrated the utility of BA in both an in vitro
      model and in a series of patients with arrhythmia resistant to unipolar ablation. When
      compared to unipolar RF ablation, BA was found to be more likely to achieve transmural
      lesions in a porcine heart model (33% vs 82%, respectively, p = 0.001) and could do so in
      tissue up to 25 mm thickness. Clinically, all septal atrial flutters, 5 of 6 septal VTs, and
      2 of 4 free-wall VTs were successfully acutely terminated.

      The proposed study will further examine the role of BA in patients with ventricular
      tachycardia resistant to standard ablation techniques.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Freedom from recurrent VT</measure>
    <time_frame>6 months</time_frame>
    <description>Freedom from recurrent VT at 6 months, defined as sustained ventricular tachycardia lasting longer than 30 seconds and identified due to clinical symptoms or during device interrogation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural complications</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of procedural complications which includes death, stroke, MI, heart failure, conduction abnormalities, pericardial effusion requiring drainage, hematoma, pseudoaneurysm</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-ablation inducibility</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of the induction of any sustained arrhythmia post-ablation, with a duration &gt; 15 seconds of MMVT. Post ablation inducibility is measured via program stimulation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to termination</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total duration of bipolar ablation</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Ventricular Tachycardia</condition>
  <arm_group>
    <arm_group_label>Bipolar Ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients who meet inclusion criteria and have VT not terminable with unipolar ablation will undergo bipolar ablation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bipolar Ablation</intervention_name>
    <description>Patients will undergo bipolar ablation if unipolar ablation unsuccessful</description>
    <arm_group_label>Bipolar Ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  â‰¥ 18 years of age.

          -  The study will include all forms of scar VT--both ischemic (post-myocardial
             infarction) and non-ischemic (eg sarcoid, amyloid, dilated)--as determined by cardiac
             MRI and/or voltage mapping at the time of VT ablation.

          -  Intramural VT not terminable with unipolar ablation once enrolled in the Bipolar study
             or previous failed unipolar ablation within 6 months prior to enrollment.

          -  Ability to understand the requirements of the study and sign the informed consent
             form.

          -  Willingness to adhere to study restrictions and comply with all post- procedural
             follow-up requirements

          -  Projected lifespan greater than 1 year.

        Exclusion Criteria:

          -  Tissue Thickness less than 5 mm as assessed by electroanatomic mapping, CT, or MRI.

          -  MI or CABG within 6 weeks.

          -  NYHA Class IV CHF.

          -  Women known to be pregnant or to have positive beta-HCG.

          -  Participation in another study that would interfere with this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Srinivas Dukkipati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Betsy A Ellsworth, MSN</last_name>
    <phone>212-824-8902</phone>
    <email>betsy.ellsworth@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stephanie Harcum, BA</last_name>
    <phone>212-824-8927</phone>
    <email>stephanie.harcum@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Del Priore, RN</last_name>
      <phone>708-216-2644</phone>
      <email>jdelpri@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>David Wilber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Womans Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Pelligrini, MSN, MHSA</last_name>
      <phone>617-732-5241</phone>
      <email>cpellegrini@partners.org</email>
    </contact>
    <investigator>
      <last_name>Usha Tedrow, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jen Kaufman</last_name>
      <phone>617-632-8956</phone>
      <email>jmkaufma@bidmc.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Elad Anter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Ellsworth, MSN</last_name>
      <phone>212-824-8902</phone>
      <email>betsy.ellsworth@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Stephanie Harcum, BA</last_name>
      <phone>212-824-8927</phone>
      <email>stephanie.harcum@mountsinai.org</email>
    </contact_backup>
    <investigator>
      <last_name>Srinivas Dukkipati, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Gnap</last_name>
      <phone>215-615-0781</phone>
      <email>mary.gnap@uphs.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Pasquale Santangeli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deb Cardinal</last_name>
      <phone>512-458-9410</phone>
      <email>dscardinal@austinheartbeat.com</email>
    </contact>
    <investigator>
      <last_name>Andrea Natale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Czechia</country>
  </removed_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2015</study_first_submitted>
  <study_first_submitted_qc>February 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Srinivas Dukkipati</investigator_full_name>
    <investigator_title>Co-Director EP Service</investigator_title>
  </responsible_party>
  <keyword>VT</keyword>
  <keyword>Refractory VT</keyword>
  <keyword>VT Storm</keyword>
  <keyword>Ventricular Fibrillation</keyword>
  <keyword>V Fib</keyword>
  <keyword>VF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tachycardia</mesh_term>
    <mesh_term>Tachycardia, Ventricular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

